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Abstract 
BACKGROUND: Low back pain (LBP) is the symptom of a group of syndromes with heterogeneous 
underlying mechanisms and molecular pathologies, making treatment selection and patient prognosis very 
challenging. Moreover, symptoms and prognosis of LBP are influenced by age, gender, occupation, habits, 
and psychological factors. LBP may be characterized by an underlying inflammatory process. Previous 
studies indicated a connection between inflammatory response and total plasma N-glycosylation. We wanted 
to identify potential changes in total plasma N-glycosylation pattern connected with chronic low back pain 
(CLBP), which could give an insight into the pathogenic mechanisms of the disease. 
METHODS: Plasma samples of 1128 CLBP patients and 760 healthy controls were collected in clinical 
centers in Italy, Belgium and Croatia and used for N-glycosylation profiling by hydrophilic interaction ultra-
performance liquid chromatography (HILIC-UPLC) after N-glycans release, fluorescent labeling and clean-
up. Observed N-glycosylation profiles have been compared with a cohort of 126 patients with acute 
inflammation that underwent abdominal surgery. 
RESULTS: We have found a statistically significant increase in the relative amount of high-branched (tri-
antennary and tetra-antennary) N-glycan structures on CLBP patients’ plasma glycoproteins compared to 
healthy controls. Furthermore, relative amounts of disialylated and trisialylated glycan structures were 
increased, while high-mannose and glycans containing bisecting N-acetylglucosamine decreased in CLBP. 
CONCLUSIONS: Observed changes in CLBP on the plasma N-glycome level are consistent with N-
glycosylation changes usually seen in chronic inflammation. 
GENERAL SIGNIFICANCE: To our knowledge, this is a first large clinical study on CLBP patients and 
plasma N-glycome providing a new glycomics perspective on potential disease pathology. 
 
Keywords: glycan biomarker; low back pain; plasma N-glycosylation; retrospective study  
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Abbreviations 
% Area: percentage of total integrated area of the chromatogram; 2-AB: 2-aminobenzamide; 2-PB: -picoline 
borane; AbSur: cohort of patients with acute inflammation that had abdominal surgery; ACE: automatic 
chromatogram extraction; ADCC: antibody-dependent cell-mediated cytotoxicity; ANCOVA: analysis of 
covariance; B - N-glycans that contain bisecting N-acetylglucosamine, BEL: samples from clinical centers in 
Belgium; CLBP: chronic low back pain; CRO: samples from clinical centers in Croatia; DMSO: dimethyl 
sulfoxide; FA: formic acid; FDR: false discovery rate; G0: agalactosylated N-glycans; G1: 
monogalactosylated N-glycans; G2: digalactosylated N-glycans; G3: trigalactosylated N-glycans; G4: 
tetragalactosylated N-glycans; GlcNAc: N-acetylglucosamine; GPs: glycan peaks; GU: glucose unit; HB - 
highly branched N-glycans; HILIC-SPE: hydrophilic interaction liquid chromatography solid phase 
extraction; HILIC-UPLC: hydrophilic interaction ultra-performance liquid chromatography; HM - high-
mannose N-glycans; IgG: immunoglobulin G; ITA: samples from clinical centers in Italy; LB: low branched 
N-glycans; LBP: low back pain; LDD: lumbar disc degeneration; META: meta-analysis; MS: mass 
spectrometry; PBS: phosphate buffered saline; S0: neutral/not sialylated N-glycans; S1: monosialylated N-
glycans; S2: disialylated N-glycans; S3: trisialylated N-glycans; S4: tetrasialylated N-glycans; SDS: sodium 
dodecyl sulfate; UPLC: ultra-performance liquid chromatography  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
1. Introduction 
Low back pain (LBP) includes several mixed pain syndromes being one of the most common health 
problems in the world. Almost every adult has or will experience an episode of LBP and it is the number one 
cause of years lived with disability [1]. Prevalence of several frequently overlapping sources of LBP include 
sacroilitis 25-32 % [2,3], lumbal spondylosis 36-42 % [4–6], spinal stenosis, or lumbar 
radiculitis/radiculopathy up to 30 % [7,8]. When muscle tension, stiffness or pain are localized above the 
inferior gluteal folds and below the coastal margin, with or without leg pain, and last for three months or 
more, the condition is classified as chronic low back pain (CLBP). This is a group of syndromes with 
heterogeneous variable underlying mechanisms and molecular pathologies that correlate poorly with spine 
imaging. Additionally, symptoms and prognosis are influenced by many factors (gender [9], age [10], 
occupation, habits [11]), as well as physiological [12] and psychological factors [13,14], making managing 
the condition very challenging. The success of interventional techniques, such as epidural steroid injection, 
facet joints denervation, spinal cord stimulation or laminectomy, depends largely on the specific 
physiopathology of each patient. However, currently there is little evidence based approach to this disease, 
as biomarkers and prognostic factors practically do not exist. 
 In complex organisms, glycans (sugar moieties covalently attached to proteins) play an important 
role in virtually all processes that involve more than one cell [15]. Nearly all membrane and secreted 
proteins are modified by glycans with variable site occupancy and glycan composition [16,17]. Absence of 
N-glycosylation is embryonically lethal [18] and mutations that obstruct proper glycosylation cause 
debilitating diseases [19]. Inter-individual differences in N-glycosylation are associated with predisposition 
for and course of different diseases [20]. This is not surprising since the glycan parts of (glyco)proteins are 
integral elements of the final molecular structure, and together with amino acids in the polypeptide 
backbone, form a single molecular entity that performs biological functions. For example, glycans attached 
to immunoglobulin G (IgG) have very profound effects on protein structure and can convert IgG from a pro-
inflammatory to an anti-inflammatory mode [21]. Alternative glycosylation (attachment of different glycans) 
affects binding of IgG to all Fc receptors and is in this way analogous to variation in protein sequence due to 
genetic variations [22].  
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 Systemic and/or local inflammatory processes are believed to be an underlying mechanism in at least 
a subgroup of LBP patients, although this is not generally recognized. Previous studies indicated that 
inflammatory response associates with changes in total plasma N-glycosylation [23], as well as N-
glycosylation of individual serum glycoproteins [24]. Since glycans affect not only protein structure, but 
also its function, a number of studies have shown that changes in glycosylation are implicated in the 
pathology of different diseases [25–28]. 
 Glycosylation of individual glycoprotein, IgG, has already been studied in the context of LBP in a 
large study of 4511 twins from the TwinsUK database [29]. IgG glycans with core fucose (have lower 
antibody-dependent cell-mediated cytotoxicity, ADCC) and IgG glycans without core fucose (have higher 
ADCC activity) have been found to correlate with LBP, suggesting the involvement of ADCC and 
inflammation in LBP pathogenesis. However, there was no correlation found between lumbar disc 
degeneration (LDD) scores and IgG glycans, implicating different pathogenic mechanisms for specific LBP 
subtypes and supporting the role of glycans in inflammation-related LBP subtypes. 
 Considering previous research on inflammatory response association with changes in total plasma N-
glycosylation [23], here, we studied the total plasma N-glycome in CLBP patients and controls in order to 
identify if there is an association between the N-glycosylation pattern on the level of total plasma 
glycoproteins and risk of CLBP condition. Specific pattern of plasma N-glycosylation could be used as a 
biomarker of CLBP, and potential indicator of both pathogenic mechanisms and therapy efficiency in future 
prospective and longitudinal studies. 
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2. Methods 
2.1. Study approval 
The study was approved by the ethical committees of the participating clinical centres between December 
2013 and March 2014 and written informed consent was obtained from each participant prior to inclusion in 
the study. Participant samples have been de-identified by code. The study has been registered on 
clinicaltrials.gov (NCT02037789). 
 
2.2. Clinical samples and data 
Retrospective plasma samples of CLBP patients and healthy controls (people without acute or CLBP) were 
collected in several clinical centers in Italy, Belgium and Croatia that are involved in PainOmics project, 
following previously established and validated protocol for blood sample collection, storage and shipping 
[30,31] (Table 1). In short, blood for glycomics analysis has been collected into EDTA containing 
vacutainer tube and mixed well for balanced clotting. Tube was left at room temperature for 1 hour and 
plasma was separated by centrifugation at 1620 g for 10 minutes, transferred to a clean tube and centrifuged 
again at 2700 g for 10 minutes. Volume of 1 mL of plasma after second centrifugation step has been 
transferred to a clean tube and stored at -80 ˚C or -20 ˚C before further processing. CLBP patients were 
defined according to previously published criteria [31]: all Caucasian adult patients, referred to participant 
pain clinics, with pain localized to the column between the costal margins and gluteal fold, with or without 
symptoms into one or both legs, that was lasting more than 12 weeks. We excluded all patients with an acute 
episode of LBP, any history of spine tumor or infection or recent (less than 12 months) vertebral fractures, 
or psychiatric disorders. All patients have been classified into 6 major groups: spinal stenosis, discogenic 
pain, facet joint pain, sacroiliac joint pain, low back pain associated to radicular pain (radicular pain not 
predominant) and wide-spread LBP. Furthermore, all patients’ pain characteristics (intensity and type of 
pain) have been evaluated with painDETECT [32]. 
 Plasma samples from cohort of patients with acute inflammation that underwent abdominal surgery 
(AbSur) were collected in several clinical centers in Italy as described earlier [33,34]. Blood samples of 126 
patients have been taken in several time points - intraoperatively and 6, 12, 24, and 48 hours aſter the 
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surgery. Samples taken intraoperatively and 48 hours after abdominal surgery have been considered as 
“Case” or “Control”, respectively. In short, blood for glycomics analysis has been collected into EDTA 
containing vacutainer tube, mixed well for balanced clotting and plasma was separated by centrifugation at 
room temperature. Samples have been stored at -20 ˚C before further processing. 
 
2.3. Deglycosylation of plasma samples 
All plasma samples and in-house plasma standards were vortexed after thawing and centrifuged for 3 
minutes at 12 100 g. Each sample (10 μL) was aliquoted to 1 mL 96-well collection plates (Waters, Milford, 
MA, USA) following a predetermined experimental design, which was blocked on case-control status, sex 
and age information (each 96-well plate represents the whole population in terms of case-control status, sex 
and age distribution), while the rest was randomized. In-house plasma standards were aliquoted in four to 
five replicates per plate, to control for batch effects, that is plate-to-plate variation. 
 Plasma proteins were denatured by adding 20 μL of 2 % (w/v) sodium dodecyl sulfate (SDS, 
Invitrogen, Carlsbad, CA, USA) and sample incubation at 65 °C for 10 minutes. After cooling to room 
temperature for 30 minutes, 10 μL of 4 % (v/v) Igepal CA-630 (Sigma-Aldrich, St. Louis, MO, USA) was 
added to each sample and the mixture was shaken for 15 minutes at room temperature on a plate shaker. 
Plasma proteins were deglycosylated by incubation at 37 °C for 18 hours after 1.2 U of PNGase F (10 U μL-
1
, Promega, Madison, WI, USA) in 10 μL of 5× PBS was added to each sample. Buffer 5× PBS was made in 
house: 685 mmol L
-1 
NaCl (Carlo Erba, Peypin, Italy), 13.5 mmol L
-1
 Na2HPO4 (Acros Organics, Thermo 
Fisher Scientific, Geel, Belgium), 48.5 mmol L
-1
 KH2PO4 (Sigma-Aldrich), 11 mmol L
-1 
KCl (Gram-Mol, 
Zagreb, Croatia), and filtered through 0.2 μm Supor PES filters (Nalgene Thermo Fischer Scientific)..  
 
2.4. Fluorescent labeling and clean-up of released plasma N-glycans 
Released plasma N-glycans were subsequently labeled with a fluorescent dye 2-aminobenzamide (2-AB, 
Sigma-Aldrich). The labeling mixture was freshly prepared by dissolving 0.48 mg of 2-AB and 1.12 mg of 
2-picoline borane (2-PB, Sigma-Aldrich) in 25 μL of dimethyl sulfoxide (DMSO, Sigma-Aldrich) and 
glacial acetic acid (Merck, Darmstadt, Germany) (7:3, v/v), per sample. Labeling mixture was added to each 
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sample and the plate was sealed with an adhesive seal. Samples were mixed for 10 minutes at room 
temperature, and incubated at 65 °C for 2 hours for the labeling reaction to take place. 
 Released and fluorescently labeled plasma N-glycans were cleaned of excess of reagents and proteins 
by previously developed and optimized hydrophilic interaction liquid chromatography solid phase extraction 
(HILIC-SPE) procedure [35]. After labelling, reaction samples were cooled down to room temperature for 
30 minutes and 700 μL of cold (4 °C) acetonitrile (Sigma-Aldrich) was added to each sample and gently 
mixed. The clean-up procedure was performed on a hydrophilic 0.2 μm AcroPrep GHP filter plate (Pall 
Corporation, Ann Arbor, MI, USA) using a vacuum manifold (Pall Corporation) at around 25 mm Hg. All 
wells of a GHP filter plate were prewashed with 200 μL of 70 % ethanol in water, 200 μL of ultra-pure 
water and 200 μL of 96 % cold (4 °C) acetonitrile in water. The samples diluted with cold acetonitrile were 
loaded to the wells, incubated on a filter for 2 minutes and subsequently washed with 5× 200 μL of 96 % 
cold (4 °C) acetonitrile in water. Glycans were eluted from a filter plate with 2× 90 μL of ultra-pure water 
after 15 minutes of shaking at room temperature and centrifugation at 164 g in each step. Combined eluates 
were stored at -20 °C until the UPLC analysis. 
 
2.5. Plasma N-glycan analysis by HILIC-UPLC 
Fluorescently labelled and purified plasma N-glycans were prepared in 75 % acetonitrile (v/v) and analyzed 
by HILIC-UPLC on an Acquity UPLC instrument (Waters) consisting of a quaternary solvent manager, 
sample manager and a fluorescence detector. The 2-AB labeled N-glycans were separated on a Waters BEH 
Glycan chromatography column, 150 × 2.1 mm i.d., 1.7 μm BEH particles, in a linear gradient of 30–47 % 
100 mmol L
-1
 ammonium formate, pH 4.4 (solvent A) and acetonitrile (solvent B) at flow rate of 0.56 mL 
min
-1
 and a 23 minutes analytical run. Samples were maintained at 10 °C before injection into the column, 
the column temperature was 25 °C and separated glycans were detected at excitation wavelengths of 250 nm 
and emission wavelength of 428 nm. The UPLC system was under the control of the Empower 3 software, 
build 3471 (Waters). Chromatograms were processed using an automatic processing method and manually 
corrected to maintain the same intervals of integration across all samples, or processed with a recently 
developed semi-supervised Automatic Chromatogram Extraction (ACE) method [36] for automated 
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alignment and detection of glycan peaks in chromatograms. The plasma N-glycan samples were all 
separated into 39 glycan peaks (GPs) and the amount of glycans in each chromatographic peak was 
expressed as percentage of total integrated area (% Area). To each detected chromatographic peak a glucose 
unit (GU) value was assigned according to external standard of hydrolysed and 2-AB labelled glucose 
oligomers (dextran ladder) which was run with every analytical UPLC batch [37]. 
 
2.5.1 Confirmation of the HILIC-UPLC plasma glycome profile 
The major glycan present in each of the reported 39 chromatographic peaks was annotated according to GU 
values, measured m/z value, recorded fragmentation spectra where applicable and according to previously 
published and annotated serum N-glycome profile [38] (Supplementary Table 1). Several representative 
samples from control and patient groups were selected and analaysed by HILIC-UPLC, as described in 
previous section, additionally hyphented to the Bruker compact Q-Tof mass spectrometer (MS), both 
controlled using HyStar software (Bruker, Bremen, Germany) version 4.1. UPLC was coupled to MS via Ion 
Booster (Bruker) ion source with aditional flow of 100 μL min-1 of acetonitrile introduced into analytical 
flow using a t-piece. Capillary voltage was set to 2250 V with nebulizing gas at pressure of 5.5 Bar. Drying 
gas was applied to source at a flow rate of 4 L min
-1
 and temperature of 100 °C, while vaporiser temperature 
was set to 220 °C and flow rate of 5 L min
-1
. Nitrogen was used as a source gas, while argon was used as 
collision gas. Ion energy was set to 5 eV, transfer time was 100 μs. Spectra were recorded in mass range 
from 50 m/z to 4000 m/z at a rate of 0.5 Hz. For MS acquisition collision energy was set to 4 eV and Rf 
4200 Vpp. Fragment spectra were acquired using auto MS/MS mode using a precursor ion list of detected 
m/z values corresponding to free 2-AB labelled plasma glycans (Supplementary Table 1). Active exclusion 
was set to one minute after three spectra and number of precursor ions was 1. All recorded spectra were 
analysed using Bruker Data Analysis software version 4.4 (Bruker). Glycan compositions and certain 
structural features were determined using GlycoMod [39] and GlycoWorkbench [40]. 
 
2.6. Statistics 
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In order to remove experimental variation from the measurements, normalization and batch correction were 
performed on the UPLC glycan data. To make measurements across samples comparable, normalization by 
total area was performed where the peak area of each of the 39 glycan containing peaks was divided by total 
area of the corresponding chromatogram. Prior to batch correction, normalized glycan measurements were 
log-transformed due to right-skewness of their distributions and the multiplicative nature of batch effects. 
Batch correction was performed on log-transformed measurements using the ComBat method (R package 
“svav3.6.0”) [41], where the technical source of variation (which sample was analyzed on which plate) was 
modeled as batch covariate. To correct the measurements for experimental noise, estimated batch effects 
were subtracted from log-transformed measurements. In addition to the 39 directly measured glycan 
containing peaks, 14 derived traits were calculated from the directly measured glycans (Table 2). These 
derived traits average particular glycosylation features across different individual glycan structures and 
consequently they are more closely related to individual enzymatic activities and underlying genetic 
polymorphisms. 
 Association analyses between disease status and glycan traits were performed using an analysis of 
covariance (ANCOVA) model with age and gender included as covariates. Analyses were first performed 
for each cohort separately and then combined using inverse-variance weighted meta-analysis (META, R 
package “metaphor v1.9-4”) [42]. Prior to the analyses, the glycan variables were all transformed to the 
standard Normal distribution (mean = 0, sd = 1) by inverse transformation of ranks to Normality (R package 
"GenABELv1.8-0", function rntransform) [43]. Using rank transformed variables in analyses makes 
estimated effects of different glycans in different cohorts comparable as transformed glycan variables have 
the same standardized variance. In case-control regression analysis, coefficients of binary predictors refer to 
a change in a glycan variable between 2 classes of binary predictors expressed in SDs. The false discovery 
rate (FDR) was controlled using the Benjamini-Hochberg procedure, and p-values corrected for multiple 
testing (with FDR cutoff set at 0.05) are shown throughout.  
 Data was analyzed and visualized using R programming language (version 3.0.1). 
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3. Results 
3.1. Glycosylation changes in three cohorts  
Patients and healthy volunteers were enrolled in the study through clinical centers in Italy (ITA), Belgium 
(BEL) and Croatia (CRO). Total plasma N-glycosylation was analysed by ultra-performance liquid 
chromatography (UPLC) (Figure 1) in 1128 CLBP patients and 760 healthy controls (Table 1). This type of 
analysis represents the first step in a biomarker discovery – a snapshot of the differences in N-glycosylation 
pattern between CLBP patients and controls 
We observed statistically significant differences in relative abundance of several major structuraly 
similar glycan groups represented as derived glycosylation traits (Figure 2, Table 2 and 3) between CLBP 
patients and healthy controls of the ITA and BEL cohorts. A similar trend was also seen in the CRO cohort, 
although not significant after correction for multiple comparisons. (Figure 2, Table 3). All glycan groups 
(derived glycosylation traits) that were shown to be significantly changed change in the same direction 
(column “effect” in Table 3) regardless of the clinical center of study participants’ enrolment, demonstrating 
consistent changes of total plasma N-glycosylation in patients with CLBP compared to controls.
On the other hand, some differences in relative abundance of several derived glycosylation traits can 
be seen between controls enrolled in different clinical centers and the same is observed for patients (Figure 
2). Since extreme care has been taken to standardize all steps of the study [30] – from blood sample 
collection to sample processing, storage and shipping, these changes can probably be attributed to 
differences in populations (e.g. different genetic and environment background), which are known to affect 
plasma glycome composition [44]. 
 
 
3.2. Changes in derived N-glycan structural features between CLBP and controls 
The relative area of chromatographic peaks corresponding to highly branched – denoted as “HB” in Table 3 
– glycan structures is increased (and, concomitantly, the % Area of chromatographic peaks corresponding to 
glycan structures with low branching – denoted as “LB” in Table 3 – is decreased) in CLBP patients 
compared to controls, which is consistent with previous findings of increased branching in chronic 
inflammation [45–47]. 
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 Interestingly, while the % Area of chromatographic peaks corresponding to monosialylated (S1) and 
tetrasialylated (S4) glycan structures were similar or lower in CLBP patients compared to controls, the 
percentage areas of disialylated (S2) and trisialylated (S3) glycan structures were increased in CLBP patients 
compared to controls (Table 3, Figure 2). 
 Unsuprisingly, changes in galactosylation levels were similar to sialylation, reflecting the fact that 
galactose is a prerequisite for glycan sialylation. A different trend can only be observed in 
monogalactosylated (G1) structures, which are lower in CLBP patients compared to controls, while 
monosialylated (S1) structures are similar or slightly lower in patients compared to controls.  
 High-mannose glycans (HM) and glycans that contain bisecting N-acetylglucosamine (B) have 
shown the same pattern of change between CLBP patients and controls (Figure 2). This decrease in % Areas 
of chromatographic peaks corresponding to HM and B glycan structures in CLBP patients compared to 
controls was statistically significant in ITA and CRO cohorts, but did not reach the statistical significance in 
BEL cohort (Table 3). 
  
3.3. Glycosylation in CLBP and inflammation 
Since similar changes in the glycome were observed in a previously analyzed AbSur cohort, we have 
compared total plasma N-glycosylation changes from AbSur study with the total plasma N-glycosylation 
changes in CLBP study (Figure 2). For the majority of derived glycosylation traits the changes in the CLBP 
patients were in the same direction as in patients with acute inflammation compared to controls, but the 
extent of the change was somewhat smaller in CLBP. This finding indicates that CLBP is associated with 
systemic inflammation in at least a subgroup of patients. However, due to the cross-sectional nature of this 
study (plasma samples collected after CLBP development), we could not investigate longitudinal changes of 
plasma N-glycome through CLBP condition development and progression, and whether a changed N-
glycomic profile during inflammation is a pre-requisite for CLBP condition development, or merely a 
consequence of CLBP progression. 
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4. Discussion 
Phenotypic diversity caused by differences in glycosylation has not been investigated to a large extent. We 
pioneered high-throughput glycomics screening of human populations in 2009 [48] and since then analysed 
over 50,000 individual glycomes through numerous clinical and epidemiological studies. Our large-scale 
glycomics studies revealed very high inter-individual variability of both, the plasma N-glycome [44] and the 
IgG glycome [49]. However, within an individual, the composition of the N-glycome was found to have 
significant short-term (in the order of weeks) stability in homeostatic conditions [50]. 
 In a previous study [29] we found, in a large cohort of twins, a correlation between LBP and IgG 
glycan modules featuring glycans that either promote or block ADCC. On the other hand, we have not found 
any correlation between LDD and glycan structures suggesting that inflammation is not connected with this 
specific subtype of LBP. Although in this study we explored one aspect of LBP, complex pathophysiology 
of this condition still remains poorly understood and biomarker potential of N-glycome not yet defined. 
Additionally, a genome wide association study of LBP in over 400,000 individuals revealed only three 
replicable associations between genetic variants (not related explicitly to glycosylation) and LBP, indicating 
that genetics has very limited potential for stratification of LBP patients (manuscript in submission). 
 Therefore, the disease mechanisms underlying the syndrome of CLBP remain incompletely 
understood, making patient prognosis and therapy challenging. Previous studies implicated protein 
glycosylation as one of the players involved in inflammation [29]. To deepen our understanding of CLBP 
pathology and potentially improve therapy efficiency on an individual patient basis, we explored changes in 
total plasma N-glycosylation in 1888 healthy individuals and CLBP patients in an international multi-center 
retrospective clinical study. 
 We found statistically significant differences in plasma N-glycosylation between patients and 
matching (by age, gender and clinical centre) healthy controls consistent with changes in glycosylation 
previously reported for chronic inflammation – an increase in the level of high-branched glycan structures 
[45–47]. Increase in N-glycan branching is a result of N-acetylglucosaminyl (GlcNAc) transferase IV 
(transfers β1,4-linked GlcNAc to tri-manosyl core creating a third antenna) and GlcNAc transferase V 
(transfers β1,6-linked GlcNAc to the tri-mannosyl core creating a fourth antenna) function [51]. One of the 
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plasma glycoproteins that contributes to majority of tri-antennary and tetra-antennary sialylated (highly 
branched) glycans is α-1-acid glycoprotein [52], which is an acute phase protein whose concentration 
significantly increases as a response to inflammatory stimuli. Interestingly, it has been shown that the 
relative abundance of total bi-antennary glycans and α1,3-fucosylated bi-, tri- and tetra-antennary α-1-acid 
glycoprotein glycan structures are increasing in acute and chronic inflammation compared to healthy 
individuals, while the relative abundance of total tri-antennary and total tetra-antennary glycans are 
decreasing [53]. Fucose bound in an α1,3 linkage to the antenna is part of a sialyl Lewis X (SLex) structure 
that consists of a terminal α2,3-sialic acid residue linked to galactose that is attached to GlcNAc. Increase in 
SLe
x
 structures is another previously identified signature of chronic inflammation [54]. 
 Increased levels of glycans with bisecting GlcNAc has been previously connected with 
inflammation, mostly on the level of IgG [55]. On the other hand, it is known that presence of bisecting 
GlcNAc during glycan synthesis prevents formation of tri-antennary and tetra-antennary glycan structures, 
causing a decrease in glycan branching [51]. Since the reative amount of high-branched glycan structures on 
the level of total plasma glycoproteins was increased in CLBP patients compared to controls, it is not 
surprising that glycans containing bisecting GlcNAc were decreased in CLBP. 
 Although high-mannose glycans are usually not very abundant in secreted proteins relative to other 
glycan types and are considered to be incomplete products of the N-glycosylation process, its importance via 
interactions with mannose receptors on macrophages and dendritic cells as part of the innate immune 
response is well recognized [56]. Additionally it has been shown that high-mannose glycans increase serum 
clearence of IgG [57] and can initiate complement pathway by binding to mannose-binding lectin [58]. 
 Observed increase in disialylated and trisialylated glycan structures in CLBP patients potentially 
indicate an increase in relative abundance of these specific glycan structures or an amount of specific 
glycoproteins carrying disialylated and trisialylated glycans, instead of a systematic increase in level of total 
plasma glycoproteins sialylation. These targeted changes in disialylated and trisialylated glycan structures in 
CLBP are a novel finding. 
 To the best of our knowledge, this is a first large clinical study on CLBP patients and healthy 
individuals providing a total plasma N-glycomics perspective and a potential biomarker for this phenotype. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
The next step would be population stratification according to their inflammatory response. We are currently 
evaluating patients with acute LBP observing if they develop or do not develop chronic pain. With this 
prospective study we plan to go a step further and evaluate a biomarker potential of glycome in acute 
systemic inflammation. 
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FIGURE LEGENDS 
Figure 1. A) Representative plasma N-glycans chromatographic profile. Glycans labeled with 2-
aminobenzamide have been separated by ultra-performance liquid chromatography (UPLC) based on 
hydrophilic interactions (HILIC). Major glycan structures are shown for each glycan containing 
chromatographic peak (GP1–GP39). B) Different plasma N-glycosylation profiles of a healthy individual 
(Control) and a chronic low back pain patient (Case). Chromatographic profiles have been overlayed and 
scaled to the highest peak. 
 
Figure 2. Changes in total plasma N-glycosylation in chronic low back pain (CLBP). Relative 
abundance (%Area, the percentage of total plasma N-glycan pool) of major plasma N-glycan groups 
(derived traits, cf. Table 2) between healthy individuals (Control) and chronic low back pain patients (Case) 
collected in three clinical centers in Italy (ITA), Belgium (BEL) and Croatia (CRO), as well as comparison 
with patients that underwent abdominal surgery (AbSur) has been shown. Data are shown as box plots. Each 
box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Lines outside the 
boxes represent the 10th and 90th percentiles. Circles indicate outliers. 
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Table 1. Information about participants enrolled in a chronic low back pain study. 
 
ITA BEL CRO 
 
Case Control Case Control Case Control 
Sample Number 375 379 567 191 186 190 
Age (med/IQR) 67 (51-76) 68 (50-77) 56 (49-67) 56 (48-65) 55 (48-65) 56 (41-65) 
Sex (F) (n/%) 201 (53.6%) 205 (54.1%) 309 (54.5%) 108 (56.5%) 120 (64.5%) 79 (41.6%) 
Plasma N-glycosylation analysis has been performed for participants from three clinical centers in Italy 
(ITA), Belgium (BEL) and Croatia (CRO). Case - chronic low back pain patients, Control - healthy 
individuals, med - median value, IQR - interquartile range. 
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Table 2. Derived glycan traits defined from 39 directly measured chromatographic peaks corresponding to 
glycans with similar structural features (Figure 1). 
Structural feature Chromatographic peaks corresponding to glycans with designated feature 
LB (Low-branching) 
GP1+GP2+GP3+GP4+GP5+GP6+GP8+GP9+GP10+GP11+GP12+GP13+GP14+GP15+G
P16+GP17+GP18+GP20+GP21+GP22+GP23 
HB (High-branching) 
GP24+GP25+GP26+GP27+GP28+GP29+GP30+GP31+GP32+GP33+GP34+GP35+GP36
+GP37+GP38+GP39 
S0 (Neutral/not sialylated glycans) GP1+GP2+GP3+GP4+GP5+GP6+GP7+GP8+GP9+GP10+GP11 
S1 (Monosialylated glycans) GP12+GP13+GP14+GP15+GP16+GP17 
S2 (Disialylated glycans) GP18 +GP20+GP21+GP22+GP23+GP24+GP25+GP26 
S3 (Trisialylated glycans) GP27+GP28+GP29+GP30+GP31+GP32+GP33+GP34+GP35 
S4 (Tetrasialylated glycans) GP36+GP37+GP38+GP39 
G0 (Agalactosylated glycans) GP1+GP2 
G1 (Monogalactosylated glycans) GP3+GP4+GP5+GP6+GP12+GP13 
G2 (Digalactosylated glycans) GP8+GP9+GP10+GP11+GP14+GP15+GP16+GP17+GP18+GP20+GP21+GP22+GP23 
G3 (Trigalactosylated glycans) GP24+GP25+GP26+GP27+GP28+GP29+GP30+GP31+GP32+GP35 
G4 (Tetragalactosylated glycans) GP33+GP34+GP36+GP37+GP38+GP39 
HM (High-mannose glycans) GP2+GP7+GP19 
B (bisecting N-acetylglucosamine 
containing glycans) 
GP2+GP3+GP6+GP9+GP11+GP12+GP15+GP17+GP21+GP23 
GP - glycan peak. LB - monoantennary and biantennary glycans, HB - tri-antennary and tetra-antennary 
glycans, S0 - glycans with no sialic acid, S1 - glycans with one sialic acid, S2 - glycans with two sialic 
acids, S3 - glycans with three sialic acids, S4 - glycans with four sialic acids, G0 - glycans with no galactose, 
G1 - glycans with one galactose, G2 - glycans with two galactoses, G3 - glycans with three galactoses, G4 - 
glycans with four galactoses, HM - high-mannose glycans, B - glycans that contain bisecting N-
acetylglucosamine. 
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Table 3. Differences in derived structural features (TRAITs, defined in Table 2) of plasma protein N-
glycans (Figure 1) between chronic low back pain cases and healthy controls in the three populations - Italy 
(ITA), Belgium (BEL) and Croatia (CRO), together with meta-analysis of all three populations (META).  
 ITA BEL CRO META 
TRAIT 
effe
ct 
SE p.val q.val 
effe
ct 
SE p.val q.val 
effe
ct 
SE p.val q.val 
effe
ct 
SE p.val q.val 
LB (Low-
branching) 
-
0.2
20 
0.0
72 
2.23
E-03 
3.47
E-03 
-
0.3
40 
0.0
81 
2.81
E-05 
3.94E-
04 
-
0.1
15 
0.1
21 
3.39
E-01 
5.05
E-01 
-
0.2
47 
0.0
49 
5.14
E-07 
1.20
E-06 
HB (High-
branching) 
0.2
21 
0.0
72 
2.18
E-03 
3.47
E-03 
0.2
84 
0.0
81 
4.76
E-04 
1.11E-
03 
0.0
91 
0.1
21 
4.48
E-01 
5.23
E-01 
0.2
23 
0.0
49 
6.25
E-06 
9.72
E-06 
S0 (Neutral) 
-
0.4
42 
0.0
71 
5.45
E-10 
3.44
E-09 
-
0.3
19 
0.0
83 
1.23
E-04 
7.26E-
04 
-
0.1
86 
0.1
21 
1.23
E-01 
3.05
E-01 
-
0.3
56 
0.0
49 
4.22
E-13 
5.91
E-12 
S1 (Monosialylated) 
0.0
27 
0.0
72 
7.05
E-01 
7.05
E-01 
0.0
08 
0.0
83 
9.27
E-01 
9.27E-
01 
-
0.1
63 
0.1
20 
1.71
E-01 
3.41
E-01 
-
0.0
12 
0.0
49 
8.03
E-01 
8.03
E-01 
S2 (Disialylated) 
0.3
44 
0.0
71 
1.36
E-06 
3.17
E-06 
0.1
60 
0.0
84 
5.56
E-02 
8.65E-
02 
0.1
90 
0.1
21 
1.16
E-01 
3.05
E-01 
0.2
54 
0.0
49 
2.79
E-07 
7.82
E-07 
S3 (Trisialylated) 
0.2
05 
0.0
73 
4.53
E-03 
5.76
E-03 
0.2
97 
0.0
82 
3.11
E-04 
1.09E-
03 
0.1
82 
0.1
21 
1.31
E-01 
3.05
E-01 
0.2
35 
0.0
50 
2.25
E-06 
3.93
E-06 
S4 (Tetrasialylated) 
0.1
14 
0.0
71 
1.07
E-01 
1.25
E-01 
0.0
48 
0.0
83 
5.59
E-01 
7.12E-
01 
-
0.0
96 
0.1
23 
4.31
E-01 
5.23
E-01 
0.0
57 
0.0
50 
2.52
E-01 
2.71
E-01 
G0 
(Agalactosylated) 
-
0.3
98 
0.0
62 
1.85
E-10 
2.59
E-09 
-
0.2
71 
0.0
77 
4.03
E-04 
1.11E-
03 
-
0.1
14 
0.1
13 
3.11
E-01 
5.05
E-01 
-
0.3
12 
0.0
44 
1.93
E-12 
1.35
E-11 
G1 
(Monogalactosylate
d) 
-
0.4
23 
0.0
71 
3.18
E-09 
1.11
E-08 
-
0.3
11 
0.0
82 
1.56
E-04 
7.26E-
04 
-
0.1
08 
0.1
19 
3.60
E-01 
5.05
E-01 
-
0.3
30 
0.0
49 
1.58
E-11 
7.36
E-11 
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G2 
(Digalactosylated) 
0.2
85 
0.0
68 
2.97
E-05 
5.94
E-05 
0.0
76 
0.0
82 
3.51
E-01 
4.91E-
01 
0.0
74 
0.1
18 
5.28
E-01 
5.69
E-01 
0.1
79 
0.0
48 
1.91
E-04 
2.43
E-04 
G3 
(Trigalactosylated) 
0.2
12 
0.0
71 
2.71
E-03 
3.80
E-03 
0.2
28 
0.0
78 
3.54
E-03 
7.07E-
03 
-
0.0
20 
0.1
22 
8.70
E-01 
8.70
E-01 
0.1
82 
0.0
48 
1.65
E-04 
2.30
E-04 
G4 
(Tetragalactosylated
) 
0.0
70 
0.0
69 
3.04
E-01 
3.27
E-01 
0.1
65 
0.0
80 
3.91
E-02 
6.85E-
02 
0.2
26 
0.1
21 
6.12
E-02 
2.86
E-01 
0.1
28 
0.0
48 
7.35
E-03 
8.58
E-03 
HM (High-mannose 
glycans) 
-
0.3
45 
0.0
64 
8.51
E-08 
2.38
E-07 
0.0
31 
0.0
79 
6.99
E-01 
8.15E-
01 
-
0.3
40 
0.1
14 
3.00
E-03 
2.10
E-02 
-
0.2
19 
0.0
46 
1.68
E-06 
3.35
E-06 
B (bisecting N-
acetylglucosamine 
containing glycans) 
-
0.4
33 
0.0
70 
7.37
E-10 
3.44
E-09 
-
0.0
22 
0.0
83 
7.85
E-01 
8.45E-
01 
-
0.3
69 
0.1
18 
1.83
E-03 
2.10
E-02 
-
0.2
81 
0.0
49 
8.20
E-09 
2.87
E-08 
Effect - beta coefficient estimated based on regression model, SE - standard error of estimated beta 
coefficient, p.val - p-value, q.val - adjusted p-value using a FDR approach. Each TRAIT represents a sum of 
chromatographic peaks corresponding to glycans with similar structural features. LB - monoantennary and 
biantennary glycans, HB - tri-antennary and tetra-antennary glycans, S0 - glycans with no sialic acid, S1 - 
glycans with one sialic acid, S2 - glycans with two sialic acids, S3 - glycans with three sialic acids, S4 - 
glycans with four sialic acids, G0 - glycans with no galactose, G1 - glycans with one galactose, G2 - glycans 
with two galactoses, G3 - glycans with three galactoses, G4 - glycans with four galactoses,  HM - high-
mannose glycans, B - glycans that contain bisecting N-acetylglucosamine 
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Graphical Abstract 
Highlights 
 Relative occurrences of high-branched plasma N-glycans are increased in chronic low back pain 
 Plasma protein N-glycosylation changes are consistent with chronic inflammation 
 Relative occurrences of disialylated and trisialylated glycans change in chronic low back pain 
 Specific glycan changes have a potential as biomarker for chronic low back pain 
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Graphics Abstract
Figure 1
Figure 2
